Hennion & Walsh Asset Management Inc. Has $4.46 Million Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Hennion & Walsh Asset Management Inc. boosted its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 18.4% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 144,094 shares of the company’s stock after buying an additional 22,441 shares during the period. Hennion & Walsh Asset Management Inc. owned approximately 0.08% of BridgeBio Pharma worth $4,455,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Quarry LP bought a new stake in shares of BridgeBio Pharma during the 4th quarter worth approximately $50,000. Assetmark Inc. raised its position in BridgeBio Pharma by 46.8% during the fourth quarter. Assetmark Inc. now owns 2,931 shares of the company’s stock valued at $118,000 after purchasing an additional 935 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in BridgeBio Pharma during the third quarter worth $132,000. Sargent Investment Group LLC bought a new position in shares of BridgeBio Pharma in the 4th quarter valued at $213,000. Finally, Atria Wealth Solutions Inc. acquired a new position in shares of BridgeBio Pharma during the 4th quarter worth $214,000. 99.85% of the stock is currently owned by institutional investors and hedge funds.

BridgeBio Pharma Trading Up 0.5 %

NASDAQ:BBIO traded up $0.13 on Friday, reaching $25.33. 7,407,595 shares of the stock traded hands, compared to its average volume of 2,501,167. BridgeBio Pharma, Inc. has a 1-year low of $16.61 and a 1-year high of $44.32. The company’s 50 day moving average is $27.38 and its 200-day moving average is $31.59. The firm has a market capitalization of $4.74 billion, a price-to-earnings ratio of -7.87 and a beta of 1.08.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.35. The firm had revenue of $211.12 million during the quarter, compared to the consensus estimate of $140.06 million. On average, equities research analysts forecast that BridgeBio Pharma, Inc. will post -3.2 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Randal W. Scott sold 1,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $28.84, for a total value of $28,840.00. Following the transaction, the director now directly owns 5,500 shares of the company’s stock, valued at approximately $158,620. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 24.66% of the company’s stock.

Analysts Set New Price Targets

BBIO has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $43.00 price objective on shares of BridgeBio Pharma in a research note on Thursday, June 20th. JPMorgan Chase & Co. upped their price objective on shares of BridgeBio Pharma from $35.00 to $45.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. Raymond James began coverage on shares of BridgeBio Pharma in a research report on Thursday, March 21st. They issued an “outperform” rating and a $45.00 target price on the stock. Evercore ISI assumed coverage on shares of BridgeBio Pharma in a report on Tuesday, May 14th. They set an “outperform” rating and a $50.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $70.00 target price on shares of BridgeBio Pharma in a report on Tuesday, May 28th. Two investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $47.21.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.